Skip to main content

Direct-to-consumer advertising under the radar: the need for realistic drugs policy in Australia

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract

Direct-to-consumer advertising of prescription medicines (DTCA-PM) is currently banned in Australia. DTCA-PM is thought to increase health-care costs by increasing demand for drugs that are both expensive and potentially harmful. However, DTCA-PM is occurring in Australia despite the current prohibition. We argue that successful regulation of the practice has been undermined as a result of changes brought about by the ongoing communications revolution, the increasing centrality of patient choice in medical decision-making and the impossibility of drawing and maintaining a sharp distinction between information and advertising. The prohibition is further threatened by recent international trade agreements. These factors make DTCA-PM inevitable and legislative and professional bodies need to acknowledge this to create a more effective health-care policy.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Australian health policy; advertising; drug; drug industry; health-care cost; prescription

Document Type: Research Article

Affiliations: Centre for Values, Ethics and the Law in Medicine

Publication date: 2007-04-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more